UNSPSC 51204100: Immunosupressant recombinant fusion proteins

This classification denotes substances produced by genetic translation of fused genes formed by the combination of nucleic acid regulatory sequences, substances called recombinant fusion proteins, that reduce a human host's humoral and/or cell-mediated defense mechanisms against deviant native cells, foreign organisms, or foreign substances (the human immune response and system thereof), thus the term IMMUNOSUPPRESSANT RECOMBINANT FUSION PROTEINS.

UNSPSC 51204100 Immunosuppressant recombinant fusion proteins is a Class code with significant mismatch between its nominal scope and the recent opportunities tagged to it; the code shows little relevant recent activity for immunosuppressant fusion proteins themselves, but instead reflects state and local demand for emergency medical supplies, pharmaceutical distribution, and naloxone procurement tied loosely or incorrectly to this classification.

The recent opportunities solicited under this code span emergency-response medical consumables, generic pharmaceutical and OTC product distribution through state cooperative purchasing vehicles, and naloxone procurement for community health initiatives. Seminole County, Florida (IFB 60459723LAS) solicited 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through quarterly deliveries, with an initial two-year term plus one-year renewal option. The City of Tampa Purchasing Department (Bid 26-P-00145) released an IFB for 169 line items of medical and first aid supplies—including respiratory equipment, cardiac monitoring electrodes, endotracheal tubes, and medical consumables—for use by the Tampa Fire Department Rescue Division, with an estimated contract value of $700,000.00 and a one-year award period plus two one-year renewal options. The Minnesota Multistate Cooperative Purchasing Alliance (RFP S1070000015802) sought multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, requiring vendors to supply through authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) with pricing weighted 75 percent in evaluation and a two-year initial term. The Texas Health and Human Services Commission (RFI HHS0017013) issued a Request for Information to gather market intelligence on direct-to-manufacturer prescription programs aimed at improving pharmacy benefit efficiency. These solicitations are issued by state health agencies, county health departments, municipal fire departments, and cooperative purchasing alliances rather than entities procuring immunosuppressant biologics.

Recent activity concentrates in Florida, Texas, and Minnesota, with a national cooperative purchasing mechanism serving multiple states. The code shows no targeted state-and-local procurement for immunosuppressant recombinant fusion proteins; vendors pursuing biologics distribution to state Medicaid programs, state university health systems, or other state health facilities should verify code assignment or search adjacent UNSPSC classifications for pharmaceutical manufacturing and distribution that better reflect immunotherapy procurement.